Gyre Therapeutics Inc (STU:L9S)
€ 13.6 -0.1 (-0.73%) Market Cap: 1.33 Bil Enterprise Value: 1.30 Bil PE Ratio: 0 PB Ratio: 21.33 GF Score: 30/100

Catalyst Biosciences, Inc. - Special Call Transcript

Feb 07, 2020 / 01:30PM GMT
Operator

Greetings, and welcome to the Catalyst Biosciences Conference Call. (Operator Instructions)

As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ana Kapor, Investor Relations at Catalyst Biosciences. Thank you. You may begin.

Ana Kapor
Catalyst Biosciences, Inc. - Senior Director of IR & Corporate Communications

Thank you, and welcome to our update call. This morning at the EAHAD 2020 meeting in The Hague, data from our Phase IIb trial for DalcA in patients with severe hemophilia B was presented in an oral session. Data from our MarzAA and Factor IX gene therapy programs were also presented in three posters. Our call today is to review the data presented and answer any questions. Joining me today from Catalyst are Dr. Nassim Usman, President and Chief Executive Officer; Dr. Howard Levy, Chief Medical Officer; and Grant Blouse, Vice President, Translational Research.

Before we begin, I would like to remind you that various remarks that we make on this call contain forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot